| Identification | Back Directory | [Name]
2,4-Thiazolidinedione, 3-[[(3Z)-2,3-dihydro-3-[[4-(4-MorpholinylMethyl)-1H-pyrrol-2-
yl]Methylene]-2-oxo-1H-indol-5-yl]Methyl]-, hydrochloride | [CAS]
1265965-19-2 | [Synonyms]
112180
2,4-Thiazolidinedione, 3-[[(3Z)-2,3-dihydro-3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methyle
(Z)-3-((3-((4-(morpholinomethyl)-1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)methyl)thiazolidine-2,4-dione hydrochloride
2,4-Thiazolidinedione, 3-[[(3Z)-2,3-dihydro-3-[[4-(4-MorpholinylMethyl)-1H-pyrrol-2-
yl]Methylene]-2-oxo-1H-indol-5-yl]Methyl]-, hydrochloride | [Molecular Formula]
C22H23ClN4O4S | [MDL Number]
MFCD28142841 | [MOL File]
1265965-19-2.mol | [Molecular Weight]
474.96 |
| Hazard Information | Back Directory | [Uses]
(Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC)[1]. | [References]
[1] Park K, et al. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation[J]. Lung Cancer, 2021, 155: 127-135. DOI:10.1016/j.lungcan.2021.03.012 |
|
| Company Name: |
ChemShuttle, Inc.
|
| Telephone: |
0510-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
|